Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 19/20 | 0.77 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.60 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.60 |
| ▸ | HTR1A | P08908 | 1/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.60 |
| ▸ | DRD2 | P14416 | 1/20 | 0.60 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.60 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.60 |
| ▸ | CNR1 | P21554 | 1/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.60 |
| ▸ | MC4R | P32245 | 1/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.60 |
| ▸ | HRH1 | P35367 | 1/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.60 |
| ▸ | DRD3 | P35462 | 1/20 | 0.60 |
| ▸ | SCN1A | P35498 | 1/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28158831 | 0.98 | SIGMAR1 (0.74) | SIGMAR1ADRB2ADRB1HTR1AADORA3 | |
| SCHEMBL4821348 | 0.95 | SIGMAR1 (0.79) | SIGMAR1ADRB2ADRB1HTR1AADORA3 | |
| SCHEMBL4821356 | 0.95 | SIGMAR1 (0.79) | SIGMAR1ADRB2ADRB1HTR1AADORA3 | |
| SCHEMBL30384619 | 0.93 | SIGMAR1 (0.86) | SIGMAR1ADRB2ADRB1HTR1AADORA3 | |
| Phenol SCHEMBL27559106 | 0.92 | SIGMAR1 (0.69) | SIGMAR1ADRB2ADRB1HTR1AADORA3 | |
| SCHEMBL20689714 | 0.91 | SIGMAR1 (0.86) | SIGMAR1ADRB2ADRB1HTR1AADORA3 | |
| SCHEMBL20689707 | 0.91 | SIGMAR1 (0.86) | SIGMAR1ADRB2ADRB1HTR1AADORA3 | |
| SCHEMBL20689723 | 0.91 | SIGMAR1 (0.86) | SIGMAR1ADRB2ADRB1HTR1AADORA3 | |
| SCHEMBL9134313 | 0.87 | SIGMAR1 (1.00) | SIGMAR1ADRB2ADRB1HTR1AADORA3 | |
| SCHEMBL711506 | 0.87 | SIGMAR1 (1.00) | SIGMAR1ADRB2ADRB1HTR1AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8614346-B2 | Methods and compositions for preparation of amphetamine conjugates and salts thereof | CAMBREX CHARLES CITY, INC. (US) | 2013-12-24 | — | — | US | claimed |
| US-20120190880-A1 | METHODS AND COMPOSITIONS FOR PREPARATION OF AMPHETAMINE CONJUGATES AND SALTS THEREOF | BLUE OWL CAPITAL CORPORATION, AS NEW AGENT | 2012-07-26 | — | — | US | claimed |
| WO-2010148305-A1 | METHODS AND COMPOSITIONS FOR PREPARATION OF AMPHETAMINE CONJUGATES AND SALTS THEREOF | CAMBREX CHARLES CITY, INC. (US) | 2010-12-23 | — | — | WO | claimed |
| EP-4547250-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | Terran Biosciences Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| US-12269818-B2 | Analogs of xanomeline | TERRAN BIOSCIENCES INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20250090554-A1 | A METHOD OF TREATING DEPRESSION BY IMMUNE MODULATION | MYND LIFE SCIENCES INC (CA) | 2025-03-20 | — | — | US | disclosed |
| US-20240368149-A1 | ANALOGS OF XANOMELINE | TERRAN BIOSCIENCES INC. | 2024-11-07 | — | — | US | disclosed |
| US-20240197681-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-20 | — | — | US | disclosed |
| EP-4313030-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | Terran Biosciences, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20240000795-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. | 2024-01-04 | — | — | US | disclosed |
| WO-2024006984-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| WO-2023129976-A1 | SALT AND SOLID FORMS OF KETANSERIN | TERRAN BIOSCIENCES, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| WO-2022212854-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. (US) | 2022-10-06 | — | — | WO | disclosed |
| US-8779191-B2 | Methods and compositions for preparing lisdexamfetamine and salts thereof | CAMBREX CHARLES CITY, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8614346-B2 | Methods and compositions for preparation of amphetamine conjugates and salts thereof | CAMBREX CHARLES CITY, INC. (US) | 2013-12-24 | — | — | US | disclosed |
| US-20120190880-A1 | METHODS AND COMPOSITIONS FOR PREPARATION OF AMPHETAMINE CONJUGATES AND SALTS THEREOF | BLUE OWL CAPITAL CORPORATION, AS NEW AGENT | 2012-07-26 | — | — | US | disclosed |
| US-20120157706-A1 | Methods and Compositions for Preparing Lisdexamfetamine and Salts Thereof | AVISTA PHARMA SOLUTIONS, INC. | 2012-06-21 | — | — | US | disclosed |
| WO-2010148305-A1 | METHODS AND COMPOSITIONS FOR PREPARATION OF AMPHETAMINE CONJUGATES AND SALTS THEREOF | CAMBREX CHARLES CITY, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190880-A1 | METHODS AND COMPOSITIONS FOR PREPARATION OF AMPHETAMINE CONJUGATES AND SALTS THEREOF | PNMT, COMT, DDT | SIGMAR1 981/4885ADRB2 1535/4885ADRB1 854/4885 |
| US-20240000795-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | HTR2A, HTR1A, HTR2C | SIGMAR1 150/4885ADRB2 90/4885ADRB1 103/4885 |
| US-20120157706-A1 | Methods and Compositions for Preparing Lisdexamfetamine and Salts Thereof | SLC6A3, COMT, LPXN | SIGMAR1 729/4885ADRB2 1350/4885ADRB1 810/4885 |
| US-20240197681-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | HTR1A, HTR2A, HTR3A | SIGMAR1 232/4885ADRB2 96/4885ADRB1 97/4885 |
| US-20240368149-A1 | ANALOGS OF XANOMELINE | HTR5A, HTR3A, HTR3B | SIGMAR1 178/4885ADRB2 307/4885ADRB1 402/4885 |
| US-12269818-B2 | Analogs of xanomeline | HTR5A, HTR3A, HTR3B | SIGMAR1 178/4885ADRB2 307/4885ADRB1 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.